期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

司库奇尤单抗在脊柱关节炎相关疾病治疗中引起结核感染的安全性进展 被引量：2

Advances in research on the safety of secukinumab in terms of tuberculosis infection in the treatment of spinal arthritis-related diseases
原文传递
导出
摘要 一直以来结核感染都是风湿科医师非常关注的问题,脊柱关节炎等疾病的治疗已经进入了生物制剂时代,而生物制剂的使用将会增加结核等机会感染的风险。司库奇尤单抗作为一种新型生物制剂,通过阻断白介素17A(IL-17A)作用,发挥免疫调节功能,用于治疗强直性脊柱炎、银屑病等效果理想,可改善患者预后、提高患者生活质量。本文就司库奇尤单抗在结核感染方面的安全性研究进行综述,以期为临床应用提供参考。 Tuberculosis infection has always been a major concern for rheumatologists.The treatment of diseases such as spinal arthritis has entered the era of biologics,but the use of biologics will increase the risk of opportunistic infections such as tuberculosis.As a novel biological agent,secukinumab can improve the prognosis and quality of life of patients with ankylosing spondylitis and psoriasis by blocking the effect of IL-17A and playing an immunomodulatory function.This article reviews the safety of secukinumab in terms of tuberculosis infection in order to provide reference for clinical application.
作者 宋晓燕 刘春红 SONG Xiao-yan;LIU Chun-hong(Department of Hematology,Yantai YEDA Hospital,Yantai 264006,China;Department of Rheumatology and Immunology,Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264100,China)
机构地区 烟台业达医院血液科 滨州医学院烟台附属医院风湿免疫科
出处 《中国新药杂志》 CAS CSCD 北大核心 2023年第12期1233-1236,共4页 Chinese Journal of New Drugs
关键词 结核感染 司库奇尤单抗 安全性 tuberculosis infection secukinumab safety
分类号 R979.5 [医药卫生—药品]
  • 相关文献

参考文献6

二级参考文献43

  • 1Global Tuberculosis Control: surveillance, planning, financing [ R ]. WHO Report 2007. Geneva, World Health Organization ( WHO/HTM/TB/2007. 376 ).
  • 2Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17- producing-CD4 + effector T cells develop via a liesgc distinct from the T helper type 1 and lineages [ J ]. Nat Immunol 2005, 6 (11): 1123-1132.
  • 3Weaver CT, Harringt on LE, Mangan PR, et al . Th17: an effector CD4 T cell lineage with regulatory T cell ties[ J]. Immunity 2006, 24 (6) : 677 - 688.
  • 4Mangan PR, Harrington LE, O' Quinn DB, et al. ransforming growth factor-beta induces development of the T (H) 17 lineage[J]. Nature 2006, 441 (7090) : 231 - 234.
  • 5Verreck FA, de Boer T, Langenberg DM,et al. Human IL-23-produeing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to ( myco ) bacteria [ J ]. PNAS 2004, 101 (13) :4560 - 4565.
  • 6Khader S, Pearl J, Sakamoto K, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available [ J ]. J lmmunol 2005, 175 : 788 - 795.
  • 7Khader SA, Cooper AM. IL-23 and IL-17 in tuberculosis[ J]. Cytokine 2008, 41 (2) :79 - 83.
  • 8Chackerian AA, Chen SJ, Brodie SJ,et al. Neutralization or Absence of the Interleukin-23 Pathway Does Not Compromise Immunity to Mycobacterial Infection [ J ]. Infect Immun 2006, 74 (11) :6092 -6099.
  • 9Happel K, Lockhart E, Mason C, et al. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs [ J ]. Infect lmmun 2005, 73 : 5782 - 5788.
  • 10Aggarwal S, Ghilardi N, Xie MH,et al. Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17 [ J ]. J Biol Chem 2003, 278 (3) : 1910 - 1914.

共引文献155

同被引文献22

引证文献2

中国新药杂志
2023年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部